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Abstract
Background: Rabson Mendenhall syndrome is a rare endocrine condition characterized by severe insulin resistance
and hyperglycemia. It occurs due to mutations in the insulin receptor gene. Few mutations which are associated
with Rabson Mendenhall syndrome have been identified and reported in the past. The management of this
condition is extremely challenging and will need multi-disciplinary approach.
Case presentation: An 11 year old boy presented with polyuria and polydipsia. He was noted to have coarse
facies, severe acanthosis nigricans, hypertrichosis, retarded growth and developmental delay. Investigations revealed
severe hyperglycemia which was poorly responsive to high doses of insulin. A diagnosis of Rabson Mendenhall
syndrome was suspected based on his physical characteristics in the presence of insulin resistance. Genetic studies
revealed a homozygous missense mutation in the Insulin receptor gene confirming the diagnosis of Rabson
Mendenhall syndrome. This is a novel mutation which has not been reported previously.
Conclusion: Rabson Mendenhall syndrome should be suspected in a patient with characteristic physical features,
severe hyperglycemia and insulin resistance. The genetic studies will not only confirm the diagnosis but also will
help in counselling. Wider collaboration is needed to identify definitive treatment options for managing this rare
condition.
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Background
Rabson Mendenhall syndrome (RMS) is a rare auto-
somal recessive disorder characterized by severe insulin
resistance due to mutations in insulin receptor gene
(INSR gene). It is characterized by coarse facial features,
growth retardation, severe acanthosis nigricans, hypertri-
chosis, dental abnormalities, large external genitalia,
fasting hyperglycaemia and hyperinsulinemia. The con-
dition has been described in few isolated case reports
and is due to mutation in gene locus INSR; 19p13.3-
p13.2. We are presenting a case due to a genetic lesion
hitherto not previously described. The unequivocal result
of genetic testing helped us to confirm the diagnosis,
counsel the parents on the management options and
discuss regarding the long term prognosis. The treatment
options are limited for this condition and controlling the
hyperglycemia is a daunting task, hence multi-disciplinary
approach is important when managing this challenging
clinical condition.
Case presentation
An 11 year old boy from a rural area in Sri Lanka
presented to us with polyuria, polydipsia of one year
duration and intermittent headache of one month
duration.
He was the first born child to second degree consan-
guineous parents from a poor socio-economic back-
ground. The antenatal and the perinatal periods were
uneventful. He was born at term with a birth weight of
2.5 kg(-2SD) and length of 46 cm (-2SD). His develop-
mental milestones were delayed, and he achieved his
pincer grasp at 2 years, was able to walk at 3 years and
spoke his first meaningful word at 4 years.
At the age of 7 years the child had developed darken-
ing of the skin involving the neck and axillae, which had
gradually increased in severity. The parents had also
noticed that this boy had excessive hair growth all over his
body. Two months prior to the current presentation he
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had become thin and was very lethargic thus prompting
parents to seek medical attention. Except for few upper
respiratory tract infections he did not have any significant
past medical problems. There were no hospital admissions
with hypoglycemia or hyperglycemia before. There is no
family history of any significant medical problems. His
two younger siblings are healthy and did not have any
dysmorphic features.
On examination he weighed 17.5 kg (-3SD), his height
was 111 cm (-6SD), head circumference 47 cm (-3SD),
weight for height was -1SD to –2SD indicating signifi-
cant growth failure. Facial dysmorphism characterized
by small head, large ears, broad nose, prognathism, mal-
occlusion of teeth were noted along with prominent
nipples. There was extensive acanthosis nigricans, hypertri-
chosis, thick finger nails and coarse hands (Figs. 1 and 2).
Examination of the cardiovascular system, respiratory
system and neurological system were apparently normal,
abdominal examination did not reveal any organomegaly
and his external genitalia appeared to be normal. The
blood pressure was 100/60and was within the normal
limits for his age. Developmental assessment showed
that his motor skills and vision were age appropriate,
but his speech was delayed and he could make only two
word sentences. Formal assessment showed that this boy
also has moderate learning difficulties.
Investigations revealed significantly raised Random
blood sugar (RBS), Fasting blood sugar (FBS)and Glycated
Hemoglobin (HbA1c) (Table 1). There was no associated
ketonuria or ketonemia. Serum electrolytes and renal
functions were within the normal range. Ultrasonography
of the renal tract revealed that both his kidneys were
significantly enlarged for the age. Measuring the insulin
levels and C-peptide levels would have been very useful at
this point, but due to the unavailability of these tests in
state hospitals and the cost we could not perform the
tests.
Fig. 1 Coarse facies
Fig. 2 Acanthosis nigricans and hypertrichosis
Table 1 The investigation results of the patient
Results Normal value
White blood cell count (WBC) 9.5 x 109/L 4-11 x 109/L
Hemoglobin 111 g/L 11.5-16 g/L
Platelet 278 x 109/L 150-400 x 109/L
Urea 3.5 mmol/L 1.78-8.5 mmol/L
Creatinine 60 umol/L 50-95 umol/L
Potassium 4.2 mmol/L 3.5-5.5 mmol/L
Sodium 138 mmol/L 136-145 mmol/L
Alanine Amino transferase 40 U/L <45 U/L
Aspartate Amino transferase 26 U/L <35 U/L
Protein -total 71 g/L 64-83 g/L
Albumin 42 g/L 35-52 g/L
Random blood sugar (RBS) 34 mmol/L 2.2-7.7 mmol/L
Fasting blood sugar (FBS) 12 mmol/L 2.2-5.49 mmol/L
HbA1c 14.2 % Normal: Less than 5.7 %
Diabetes: 6.5 % or higher
Triglycerides 1.5 mmol/L <1.695 mmol/L
Cholesterol 4.1 mmol/L <5.18 mmol/L
Thyroid stimulating
hormone (TSH)
1.2 mIU/L 6–18 years: 0.37–6.00mIU/L
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Based on the clinical findings, our patient underwent
genetic studies to detect possible mutations in the INSR
gene. Genomic DNA was isolated from the patient’s blood
sample and enriched for the coding exons of targeted
genes using hybrid capture technology. Prepared DNA
libraries were then sequenced using a next generation
sequencing technology at Fulgent Diagnostics, California,
USA. Variants were interpreted manually using locus
specific databases, literature searches, and other molecular
biological principles. A homozygous variant in the INSR
gene, NM_000208.2:c.1042A > T (p. Ile348Phe), was iden-
tified in our patients’ sample. This particular missense
mutation has not been reported previously in patients
with RMS. Polyphen2 online tool was used to assess the
effect of this novel missense mutation and it was stated as
possibly damaging.
After the initial assessment the boy was started on a
combination of Soluble and Isophane insulin 0.5U/kg/day
and then increased to 1U/kg/day. As the blood sugars
were still high, Metformin was added to counter the insu-
lin resistance. Subsequently the dose of Insulin was further
increased to achieve normal glycemic control. With a
Metformin dose of 500 mg three times a day and Insulin
dose of 2U/kg/day the blood sugar levels were maintained
below 15 mmol/L. After starting the treatment in order to
titrate the Insulin doses this boy underwent blood sugar
series test which showed that the pre-prandial sugar levels
were in the in the range of 10-12 mmol/L and post pran-
dial blood sugar levels were 12-14 mmol/L. Due to
the financial constraints on the family, expensive newer
diabetes drugs were not considered.
Referrals to the Dermatologist, Orthodontist and Endo-
crinologist were done for management of other associated
problems. Parents were counselled about the course of
the disease, management options, long term prognosis
and recurrence in the family. The counselling was very
useful to alleviate the psychological stress of the parents
and to face the challenges in dealing with a child with
RMS. None of the immediate family members of the index
patient had any physical features or biochemical abnor-
malities suggestive of Rabson Mendenhall syndrome.
Unfortunately, due to the high cost of the test, parents
and the siblings did not undergo the genetic analysis.
In our patient the diagnosis of RMS was made based
on the clinical presentation with significant acanthosis
nigricans, hirsuitism, dysmorphic characteristics, growth
retardation, insulin dependent diabetes requiring large
amounts of insulin and this was confirmed by genetic
analysis.
Discussion
The need for relatively higher dose of insulin to manage
the hyperglycaemia suggested severe insulin resistance
in our patient. Insulin resistance is defined as “a state of
a tissue in which a greater than normal amount of insu-
lin is required to elicit a quantitatively normal response”
[1]. Synthesis of insulin receptors is regulated by INSR
gene, hence mutations in these genes will lead to insulin
resistance.
Insulin receptors are heterotetrameric receptors con-
sisting of two (α) and two (β) subunits. Insulin binds to
the extracellular subunits of its receptor and activates
the intracellular tyrosine kinase in the transmembrane
subunits [2]. Tyrosine kinase phosphorylates and recruits
certain intracellular intermediates such as insulin-like
substrates 1 and 2, Shc, and Gab1 [3]. These intermediate
substances activate other signalling molecules like Growth
factor receptor-bound protein 2, Cytoplasmic protein
Nck, tyrosine phosphatase and the phosphoinositide
3-kinase, amplifying the initial effect generated by the
insulin binding to its receptor. These complex interactions
finally produce the expected insulin effects like uptake of
glucose and amino acid by the cells, glycogenesis, fatty
acid synthesis and cholesterol synthesis. In addition, insu-
lin inhibits gluconeogenesis in the liver [2]. Any defects at
any of the above mentioned steps of this complex pathway
can lead to insulin resistance.
Many syndromes and conditions are currently identi-
fied with insulin resistance. The common clinical condi-
tions with insulin resistance due to receptor problems
are Type A insulin resistance syndrome, HAIR-AN syn-
drome, Donohue syndrome and Rabson Mendenhall
syndrome (RMS) [1, 4]. The pathophysiology of RMS is
explained by abnormality of the INSR gene at the gene
map locus 19p13.2. (OMIM: 609968, 246200, 262190)
resulting in severe biallelic loss-of-function of the insulin
receptor and impaired insulin binding [3, 5].
The RMS was first described by Rabson and Menden-
hall in 1956.They described three siblings with Insulin-
resistant diabetes mellitus having characteristic facial,
skin, skeletal and dental features [6]. RMS is charac-
terized by growth retardation, coarse facies, and skin mani-
festations such as hyperpigmentation, acanthosis nigricans
and hypertrichosis. Dental abnormalities, enlarged phallus
in males, clitoromegaly in females, nephromegaly, nephro-
calcinosis, paradoxical fasting hypoglycemia, postprandial
hyperglycemia, severe insulin resistance and hyperinsuline-
mia are other associated findings. [7] The paradoxical
fasting hypoglycaemia is explained by inappropriately
elevated insulin levels during fasting due to the excessive
production of insulin and the prolonged half-life of
the hormone signalling via the Insulin-like growth factor
type 1 (IGF-1) receptor [7]. With time these patients
progress to persistent hyperglycaemia and diabetic ketoa-
cidosis. This is due to progressive decline of insulin levels,
which is inadequate to prevent glucose synthesis in the
liver and prevent release of fatty acid by adipocytes (7).
Acanthosis nigricans, hypertrichosis and nephromegaly is
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too believed to be due to aberrant insulin signalling on
skin and other tissues mediated through activation of
IGF-1 receptor [8].
Although RMS and Donohue syndrome have many
similarities, RMS is distinguished by the presence of less
severe clinical symptoms, more severe coarse features,
dysplastic dentition, gingival hyperplasia, pineal gland
hyperplasia, diabetic ketoacidosis and survival beyond
infancy. Donohue syndrome is characterized by unique
facial features like globular eyes, micrognathia, severe intra
uterine growth retardation, lipoatrophy, early onset severe
fasting hypoglycemia and early infantile death [9–11].
Our patient had most of the clinical features suggest-
ive of RMS. Interestingly he did not have some features
such as phallic enlargement, nephrocalcinosis and fast-
ing hypoglycemia. Absence of fasting hypoglycemia can
be expected in this age because as the disease progresses
children with RMS tend to develop persistent hypergly-
cemia [7]. For confirmation of the diagnosis of RMS,
he underwent genetic analysis which revealed a novel
homozygous variant in the INSR gene, NM_000208.2:
c.1042A > T (p. Ile348Phe). Various INSR mutations
have been reported previously in patients with RMS
(Table 2) [12]. An exhaustive literature survey revealed
that this will be the first genetically confirmed published
case of RMS with the genetic mutation p. Ile348Phe. A
similar amino acid conversion was observed in another
reported case of RMS, but situated 27 amino acids away
from the mutation reported in our patient, hence the
mutation in our patient is unique and novel [12].
Several therapeutic options are currently available
for managing children with RMS. Metformin and Pio-
glitazone are effective in the initial period of the manage-
ment [13]. Exogenous insulin in high doses can be helpful
when there is uncontrolled hyperglycemia and ketoaci-
dosis, but in long run usually fails to provide adequate
glycaemic control [1, 14]. New treatment modalities
like recombinant IGF-1 and subcutaneous Leptin have
shown promising results, but those have been tried only
in a few cases [15]. But despite all these measures, the
long term prognosis of patients with RMS remains
poor until now. Hence we believe that depth research
and international collaboration is required to identify
new therapeutic options for children with this challenging
condition.
Conclusion
Rabson Mendenhall can be clinically suspected based on
characteristic physical features and metabolic derange-
ments. But genetic studies should be done to confirm
the diagnosis. Although the developing countries lack
the genetic testing facilities the genetic results will un-
doubtedly help to identify the mutation, discuss about the
nature of the disease, management options, long term
consequences and predict the recurrence in the family. It
will also facilitate to screen the asymptomatic immediate
family members. So all efforts should be made to develop
cost effective genetic and molecular testing in developing
countries. Wider collaboration is needed to share the new
knowledge about the treatment modalities available for
managing this unique and difficult condition.
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11 Arg86X Mu p.Asp261_Leu262insLeuHisLeuVal
12 IVS4-2A > G c.2480-2487del
13 Ile321Phe
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